secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2026-08-06T11:15:24+00:00
Accession:  0001764013-26-000100
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q1 FY2026 net loss of $153.2M; cash $797.8M, pipeline on track
--------------------------------------------------------------------------------

- Net loss of $153.2M ($0.75/share) vs $120.6M ($0.71/share) YoY; non-GAAP net loss $139.4M.
- Cash and equivalents $797.8M as of June 30, 2026, providing runway to potential IMVT-1402 launch in Graves' disease.
- R&D expenses $142.6M (GAAP) vs $101.2M YoY, driven by IMVT-1402 clinical trial costs.
- Pipeline on track: topline data for D2T RA and CLE in H2 2026; GD and MG in 2027; CIDP and SjD in 2028.
- G&A expenses decreased to $17.7M from $26.0M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/0001764013-26-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/imvt-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001764013-26-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer